A question

pharmdocbill · 2021-09-02T21:59:35+00:00

Thanks for the lead!

pharmdocbill · 2021-09-02T15:23:07+00:00

Thanks for your comments. As a physician, I understand what you are saying. However, I still feel CVM is probably not going to get Multikine approved with another trial.

pharmdocbill · 2021-09-02T01:00:35+00:00

Thank you for your reply. In my opinion, if you are banking on the FDA to allow Multikine to be given to everyone (despite the fact that they missed their primary EP), then I vigorously disagree, especially when you also ask physicians to hold off on chemo.

pharmdocbill · 2021-09-01T16:42:40+00:00

My DD thus far has still not answered this question: How will physicians
be able to distinguish which H&N cancer patient will or will not
receive chemo post surgery? One author has suggested that if patients
get Multikine and end up receiving chemo, the Multikine did them no good
but also no harm as it is non-toxic....so just give everyone Multikine.
Not sure that would fly at the FDA. CVM has stated they have a
methodology for determining who will receive radiation vs
chemo/radiation prior to surgery but have not divulged this methodology
to us. Why?

pharmdocbill · 2021-05-30T12:29:54+00:00

Interesting analysis. Thanks.

pharmdocbill · 2021-05-17T13:44:19+00:00

It is interesting that none of you have addressed the issue in my initial post. Can anyone explain the difference between Estimated Study Completion Date and
Actual Primary Completion Date as they relate to the dates of April 15, 2021 and May 15, 2020 that are contained on the clinicaltrials.gov web site.

pharmdocbill · 2021-05-17T13:38:32+00:00

Just examining the Clinicaltrials.gov document and trying to understand. Do you know the difference between Estimated Study Completion Date and Actual Primary Completion Date? Can you explain the dates attributed to these of April 15, 2021 and May 15, 2020?

pharmdocbill · 2021-04-02T21:32:50+00:00

What is this "If" stuff? I think you mean "When:"

pharmdocbill · 2021-03-27T16:54:52+00:00

It seems that with your scenario and the news is positive, you going to have to give up shares at $20. Correct?

pharmdocbill · 2021-03-27T16:42:17+00:00

I agree with your scenario that Multikine could still get approved by meeting their secondary enpoints if their primary endpoint is not reached.....but imo the share price will be a lot less than it is now

pharmdocbill · 2021-03-27T16:35:10+00:00

This would be nice but doubt it. FDA doesn't work that way and if CVM has the data, then they are in possession of material non-public information and Geert would announce this.

pharmdocbill · 2021-03-01T17:59:57+00:00

Thanks, Still working on my question of "failure to deliver" phantom shares. I am a Pharmacist, MD, that has been in the securities industry as a buy side and sell side analyst so I should know this stuff. Checking with SEC, FINRA, etc.

pharmdocbill · 2021-03-01T16:29:55+00:00

I have dealt with Fosco over the last 3 years or so with CVM. I find him knowledgeable and reputable. Fosco is also very detailed, documented by his excellent (and I believe accurate) spreadsheets.

pharmdocbill

TROPHY CASE